STALEY CAPITAL ADVISERS’s Matinas BioPharma MTNB Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,000	Closed	-$63.3K	–	188
2024 Q2	$63.3K	Hold	8,000	–	–	﹤0.01%	178
2024 Q1	$108K	Hold	8,000	–	–	0.01%	179
2023 Q4	$86.5K	Hold	8,000	–	–	﹤0.01%	175
2023 Q3	$52K	Sell	8,000 -4,000	-33%	-$49.1K	﹤0.01%	174
2023 Q2	$216K	Hold	12,000	–	–	0.01%	166
2023 Q1	$282K	Hold	12,000	–	–	0.02%	154
2022 Q4	$300K	Hold	12,000	–	–	0.02%	138
2022 Q3	$382K	Hold	12,000	–	–	0.02%	123
2022 Q2	$474K	Hold	12,000	–	–	0.03%	118
2022 Q1	$483K	Hold	12,000	–	–	0.02%	124
2021 Q4	$606K	Hold	12,000	–	–	0.03%	118
2021 Q3	$780K	Hold	12,000	–	–	0.04%	108
2021 Q2	$465K	Hold	12,000	–	–	0.02%	127
2021 Q1	$630K	Hold	12,000	–	–	0.04%	116
2020 Q4	$816K	Hold	12,000	–	–	0.05%	100
2020 Q3	$460K	Hold	12,000	–	–	0.03%	117
2020 Q2	$464K	Buy	12,000 +2,000	+20%	+$76.7K	0.03%	111
2020 Q1	$300K	Hold	10,000	–	–	0.03%	118
2019 Q4	$1.14M	Buy	10,000 +2,000	+25%	+$116K	0.08%	94
2019 Q3	$252K	Buy	8,000 +4,000	+100%	+$145K	0.02%	147
2019 Q2	$171K	Buy	+4,000	New	+$192K	0.01%	171

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

STALEY CAPITAL ADVISERS's MTNB Position: Q3 2024 in Review

STALEY CAPITAL ADVISERS sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 8,000 shares — an estimated $63.3K sold.

STALEY CAPITAL ADVISERS first reported a position in MTNB in Q2 2019 and held it in 21 quarters. The position peaked at $1.14M in Q4 2019. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

STALEY CAPITAL ADVISERS reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 8,000 Matinas BioPharma shares in Q3 2024, an estimated $63.3K.
STALEY CAPITAL ADVISERS first reported a position in Matinas BioPharma in Q2 2019 and held it in 21 quarters.
STALEY CAPITAL ADVISERS's Matinas BioPharma position peaked at $1.14M in Q4 2019.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2024, filed 8 Nov 2024.